Access the full text.
Sign up today, get DeepDyve free for 14 days.
R. Vigersky, Chantal Mcmahon (2019)The Relationship of Hemoglobin A1C to Time-in-Range in Patients with Diabetes.
Diabetes technology & therapeutics, 21 2
S. Colagiuri, C. Lee, T. Wong, B. Balkau, J. Shaw, K. Borch-Johnsen (2010)Glycemic Thresholds for Diabetes-Specific Retinopathy
Diabetes Care, 34
R. DeFronzo (2004)Pathogenesis of type 2 diabetes mellitus.
The Medical clinics of North America, 88 4
D. Ryan, M. Espeland, G. Foster, S. Haffner, V. Hubbard, K. Johnson, S. Kahn, W. Knowler, S. Yanovski (2003)Look AHEAD (Action for Health in Diabetes): design and methods for a clinical trial of weight loss for the prevention of cardiovascular disease in type 2 diabetes.
Controlled clinical trials, 24 5
James Anderson, E. Konz, Robert Frederich, C. Wood (2001)Long-term weight-loss maintenance: a meta-analysis of US studies.
The American journal of clinical nutrition, 74 5
S. Samson, A. Garber (2014)Metabolic syndrome.
Endocrinology and metabolism clinics of North America, 43 1
M. Franz, J. Boucher, S. Rutten-Ramos, J. Vanwormer (2015)Lifestyle weight-loss intervention outcomes in overweight and obese adults with type 2 diabetes: a systematic review and meta-analysis of randomized clinical trials.
Journal of the Academy of Nutrition and Dietetics, 115 9
R. Beck, R. Bergenstal, Tonya Riddlesworth, C. Kollman, Zhaomian Li, Adam Brown, Kelly Close (2018)Validation of Time in Range as an Outcome Measure for Diabetes Clinical Trials
Diabetes Care, 42
T. Haak, H. Hanaire, R. Ajjan, N. Hermanns, J. Riveline, G. Rayman (2016)Flash Glucose-Sensing Technology as a Replacement for Blood Glucose Monitoring for the Management of Insulin-Treated Type 2 Diabetes: a Multicenter, Open-Label Randomized Controlled Trial
Diabetes Therapy, 8
Edward Gregg, Haiying Chen, Lynne Wagenknecht, Jeanne Clark, L. Delahanty, J. Bantle, Henry Pownall, Karen Johnson, Monika Safford, Abbas Kitabchi, F. Pi-Sunyer, R. Wing, Alain Bertoni (2012)Association of an intensive lifestyle intervention with remission of type 2 diabetes.
JAMA, 308 23
J. Skyler, R. Bergenstal, R. Bonow, J. Buse, P. Deedwania, E. Gale, B. Howard, M. Kirkman, M. Kosiborod, P. Reaven, R. Sherwin (2009)Intensive Glycemic Control and the Prevention of Cardiovascular Events: Implications of the ACCORD, ADVANCE, and VA Diabetes Trials
Diabetes Care, 32
Yurong Zhang, G. Hu, Zuyi Yuan, Liwei Chen (2012)Glycosylated Hemoglobin in Relationship to Cardiovascular Outcomes and Death in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis
PLoS ONE, 7
S. Yagihashi, H. Mizukami, K. Sugimoto (2010)Mechanism of diabetic neuropathy: Where are we now and where to go?
Journal of Diabetes Investigation, 2
Satoshi Ida, R. Kaneko, K. Murata (2019)Utility of Real-Time and Retrospective Continuous Glucose Monitoring in Patients with Type 2 Diabetes Mellitus: A Meta-Analysis of Randomized Controlled Trials
Journal of Diabetes Research, 2019
K. Johansson, M. Neovius, E. Hemmingsson (2013)Effects of anti-obesity drugs, diet, and exercise on weight-loss maintenance after a very-low-calorie diet or low-calorie diet: a systematic review and meta-analysis of randomized controlled trials123
The American Journal of Clinical Nutrition, 99
E. Cengiz, W. Tamborlane (2009)A tale of two compartments: interstitial versus blood glucose monitoring.
Diabetes technology & therapeutics, 11 Suppl 1
S. Inzucchi, R. Bergenstal, J. Buse, M. Diamant, E. Ferrannini, M. Nauck, A. Peters, A. Tsapas, R. Wender, D. Matthews (2014)Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes
Diabetes Care, 38
M. Bergman, M. Abdul-Ghani, R. DeFronzo, M. Manco, G. Sesti, Teresa Fiorentino, A. Ceriello, M. Rhee, L. Phillips, S. Chung, Celeste Cravalho, R. Jagannathan, L. Monnier, C. Colette, D. Owens, C. Bianchi, S. Prato, M. Monteiro, João Neves, José Medina, M. Macedo, Rogério Ribeiro, João Raposo, Brenda Dorcely, Nouran Ibrahim, M. Buysschaert (2020)Review of Methods for Detecting Glycemic Disorders.
Diabetes research and clinical practice
A. Adler, I. Stratton, A. Neil, J. Yudkin, D. Matthews, C. Cull, A. Wright, R. Turner, R. Holman (2000)Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study
BMJ : British Medical Journal, 321
L. Aiello, T. Gardner, G. King, G. Blankenship, J. Cavallerano, F. Ferris, R. Klein (1998)Diabetic retinopathy.
Diabetes care, 21 1
D. Nathan (2013)The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study at 30 Years: Overview
Diabetes Care, 37
M. Gabbay, M. Rodacki, L. Calliari, A. Vianna, M. Krakauer, M. Pinto, J. Reis, Márcia Puñales, Leonardo Miranda, A. Ramalho, D. Franco, H. Pedrosa (2020)Time in range: a new parameter to evaluate blood glucose control in patients with diabetes
Diabetology & Metabolic Syndrome, 12
J. Meigs, D. Nathan, R. D'Agostino, P. Wilson (2002)Fasting and postchallenge glycemia and cardiovascular disease risk: the Framingham Offspring Study.
Diabetes care, 25 10
W. Polonsky, D. Hessler, K. Ruedy, R. Beck (2017)The Impact of Continuous Glucose Monitoring on Markers of Quality of Life in Adults With Type 1 Diabetes: Further Findings From the DIAMOND Randomized Clinical Trial
Diabetes Care, 40
Ryan Lee, T. Wong, C. Sabanayagam (2015)Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss
Eye and Vision, 2
[Over 34 million Americans have diabetes, of which up to 95% have type 2 diabetes mellitus (T2DM) (Centers for Disease Control (CDC). 2019 National Diabetes Fact Sheet [Internet], last reviewed May 30, 2019. Available at https://www.cdc.gov/diabetes/basics/type2.html). T2DM is an independent risk factor for cardiovascular disease and a leading cause of kidney failure, blindness, and numerous other complications. It is therefore critical for clinicians to recognize the risk factors and underlying physiology that contribute to the development of T2DM. Appropriate screening, lifestyle interventions, glycemic targets, methods of self-monitoring, and clinical management of T2DM and its sequelae (micro- and macrovascular complications) will be reviewed in this chapter.]
Published: Jan 4, 2022
Keywords: Type 2 diabetes (T2DM); Screening; Lifestyle modification; Time in range (TIR); Glycemic targets; Macrovascular complications; Microvascular complications
Access the full text.
Sign up today, get DeepDyve free for 14 days.